N/A N=187 Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial
Hot Flashes
Primary: Hot Flash Frequency — 27.19; 68.26; 19.44; 62.32 hot flashes per week
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=29 Impact of Hot Flashes on Sleep and Mood Disturbance
Menopause · Depression · Hot Flashes
Primary: Percent Change in Wake After Sleep Onset (WASO) — 62 percent change — p=0.007
N/A N=250 A Mind-Body Intervention for Hot Flash Management
Hot Flashes · Postmenopausal Symptoms · Breast Cancer
Primary: Hot Flash Daily Diary — 88.7; 94.6; 41.3; 55.9 Hot Flash Score
Phase 3 N=150 Oxybutynin Chloride in Managing Hot Flashes
Breast Carcinoma · Ductal Breast Carcinoma In Situ · Hot Flashes
Primary: Average Change in Hot Flash Activity Score From Baseline to Week 7 for Low Dose Oxybutynin vs Placebo and for High Dose Oxybutynin vs Placebo — -16.9; -10.6; -5.7 score…
N/A N=50 EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer
Breast Carcinoma · Breast Ductal Carcinoma In Situ · Breast Lobular Carcinoma In Situ
Primary: Device Usage
Phase 2 N=356 Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
Menopausal and Female Climacteric States
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) and Number of Participants With Mild, Moderate and Severe AE — 54; 52; 45; 51 Participants
N/A N=8 HIRREM Hot Flashes Study
Vasomotor Symptoms · Hot Flashes · Menopause
Primary: Reduction in Hot Flash Severity Score Based on Diary Data — -0.39; -0.38 score on a scale
N/A N=36 Vilazodone for Menopausal Hot Flashes
Hot Flushes
Primary: Daily Diary Ratings of Frequency of Hot Flashes — 3.65; 4.71 number of hot flashes — p=0.05
N/A N=27 Wrist Cooling for Hot Flashes Clinical Trial
Hot Flashes
Primary: Number and Severity of Hot Flashes — 1148; 692; 924; 1213 number of hot flashes
Phase 3 N=27 Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes.
Breast Cancer · Hot Flashes
Primary: Number of Daily Hot Flashes — 5; 4.5 daily hot flashes
Phase 1 N=103 Study of Erenumab (AMG 334) in Women With Hot Flashes
Vasomotor Symptoms; Hot Flashes
Primary: Ratio of Week 4 to Baseline Average Number of Daily Moderate to Severe Hot Flashes — 0.35; 0.38 ratio — p=0.723
Phase 3 N=501 A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
Hot Flashes
Primary: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 — -3.72; -5.53; -6.26 VMS per day — p=<0.001
Phase 4 N=20 Understanding Experimentally Induced Hot Flushes
Hot Flashes
Primary: Percent Change in Objective Sleep Efficiency — -2.6; 4.2 percent change
Phase 3 N=527 A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
Hot Flashes
Primary: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 — -3.32; -5.19; -5.39 VMS per day — p=<0.001
Phase 2 N=141 Flushing Reduction Associated With Nitrates
Menopausal Hot Flashes
Primary: Change From Baseline Hot Flash Frequency — -4.56; -4.02 Hot flashes per day — p=0.34
N/A N=38 Reducing the Experience of Menopausal Symptoms Through Temperature
Hot Flashes · Menopause
Primary: Hot Flash Diary — 9 number of hot flashes per week
Phase 2 N=43 Evaluation of SAMe for Hot Flashes
Healthy, no Evidence of Disease · Hot Flashes
Primary: Percent of Baseline in Average Hot Flash Activity (Score and Frequency) — 64.6; 67.4 Percent of baseline — p=0.0903
Phase 3 N=191 Pregabalin in Treating Women With Hot Flashes
Breast Cancer · Hot Flashes
Primary: Numerical Change From Baseline in Hot Flash Score at Treatment Week 6 (Positive Numbers to Represent Increases and Negative Numbers to Represent Decreases). — -9.6; -6.1…
N/A N=28 The Role of Serotonin in Hot Flashes After Breast Cancer
Breast Cancer
Primary: Serum Tryptophan Levels — 0.0034; 0.02 nmol/ml
Phase 2 N=356 A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
Menopause · Hot Flashes
Primary: Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 — -4.2; -6.1; -7.2; -7.0 VMS per…
N/A N=205 MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women
Hot Flashes · Menopause · Vasomotor Symptoms
Primary: Daily Frequency of Hot Flashes Per Day Assessed by Prospective Daily Diaries — 9.88; 9.66 Hot flashes/day
Phase 2 N=29 Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer
Breast Cancer · Cancer Survivor · Hot Flashes
Primary: Percent Difference in Hot Flash Activity (Score) Between Baseline and End of Treatment (Week 5) — -50.4 percentage of difference
Phase 3 N=210 Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy
Breast Cancer · Hot Flashes · Menopausal Symptoms
Primary: To Evaluate the Efficacy of Flaxseed on Hot Flash Scores in Women as Measured by a Daily Prospective Hot Flash Diary. — -4.9; -3.5 units on a scale — p=0.29
Phase 2 N=82 Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
Prostate Carcinoma
Primary: Change in Weekly Patient-reported Hot Flash Scores — -9.94; -13.95; -4.85 units on a scale — p=0.0019
Phase 3 N=396 A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause
Vasomotor Symptoms Associated With Menopause · Hot Flashes
Primary: Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD]). — 13.38; 14.26; -7.48; -4.37 Hot Flashes per day…
N/A N=92 Three Different Programs of Paced Breathing in Treating Hot Flashes in Women
Breast Cancer · Fatigue · Hot Flashes
Primary: The Difference in Hot Flash Score (Frequency and Severity) Between Baseline (Week 1) and Week 9 — -6.5; -7.5; -6.5 units on a scale — p=0.3679
Phase 3 N=400 A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
Vasomotor Symptoms Associated With Menopause · Hot Flashes
Primary: Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD) — 14.66; 16.16; -8.58; -6.07 Hot Flashes per day — p=< 0.0001
Phase 2 N=87 Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes
Hot Flashes
Primary: Change From Baseline to Week 12 in The Weekly General Hot Flash Score — -12.19; -26.51 score on a scale — p=<0.001
N/A N=78 Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial
Breast Cancer
Primary: Change From Baseline in Mean Weekly HFS Score Between Acupuncture and Usual Care Arms at the End of Week 10 — -5.3; -0.5 HFS score on a scale — p=0.0003
Phase 4 N=60 Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia
Insomnia
Primary: Within-person Change in ISI Score — -8.1; -5.6 score on a scale